secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001213900-24-060281
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron receives FDA RMAT designation for Lomecel-B in mild Alzheimer's disease
--------------------------------------------------------------------------------

- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Lomecel-B for mild Alzheimer's disease.
- Lomecel-B is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer's disease.
- CLEAR MIND Phase 2a trial met primary safety and secondary efficacy endpoints; full results at AAIC on July 28, 2024.
- This is the fourth special FDA designation for Lomecel-B; HLHS program holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
- RMAT designation enables intensive FDA guidance and potential expedited review and accelerated approval pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024060281/0001213900-24-060281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024060281/ea0209181-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-060281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer